Devices/Safety Alert·openFDA/device

FreeStyle Libre 2 (Abbott Diabetes Care Inc) — Malfunction

MediumPublished Aug 31, 2026· AI-analyzed Sep 9, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

A malfunction was reported involving the FreeStyle Libre 2 system, manufactured by Abbott Diabetes Care Inc. The source identifies the event type as a malfunction but does not provide specific details regarding the nature of the failure.

Who it affects

This report affects Abbott Diabetes Care Inc., manufacturers of continuous glucose monitoring systems, and professionals involved in device safety monitoring and quality compliance.

Why it matters

The report of a malfunction for a high-utilization class II device necessitates close monitoring of post-market data. While the source does not detail the failure mode, such reports typically trigger internal investigations into manufacturing consistency, software reliability, or sensor performance to determine if the issue represents a systemic risk.

Practical takeaway

Regulatory and QA teams should ensure that post-market surveillance systems are actively capturing and classifying device malfunctions to meet reporting requirements. Internal CAPA processes should be reviewed to verify that malfunction trends for continuous glucose monitoring systems are being adequately addressed.

FDA source material

Event type: Malfunction. Device: FreeStyle Libre 2 by Abbott Diabetes Care Inc.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.